Effects of a mao-b inhibitor in the treatment of alzheimer disease

A. Mangoni, M. P. Grassi, L. Frattola, R. Piolti, S. Bassi, A. Motta, A. Marcone, S. Smirne

Research output: Contribution to journalArticlepeer-review


119 patients were enrolled in a double-blind randomized parallel study versus placebo carried out to assess both the efficacy and tolerability of L-deprenyl (10 mg/day) for treatment of patients with organic mental disorders of the Alzheimer type (DAT). The treatments were given for 3 months, starting after a run-in period of 15 days to evaluate efficacy. A complete neuropsychological battery was administered monthly after the start of treatment whereas tolerability was assessed by checking, recording and classifying all the unfavorable experiences occurring. According to the results, L-deprenyl would seem to be a useful and reliable tool for the treatment of DAT patients in an attempt to improve their cognitive functions and reduce behavioral alterations, without frequent or severe side effects.

Original languageEnglish
Pages (from-to)100-107
Number of pages8
JournalEuropean Neurology
Issue number2
Publication statusPublished - 1991


  • Alzheimer’s disease
  • L-Deprenyl
  • MAO-B inhibition
  • Organic mental disorders

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Effects of a mao-b inhibitor in the treatment of alzheimer disease'. Together they form a unique fingerprint.

Cite this